司美格鲁肽治疗代谢功能障碍相关脂肪性肝炎:2025年11月AASLD实践指南更新
该实践建议是对2023年AASLD非酒精性脂肪性肝病(现称MASLD)实践指南的更新,针对司美格鲁肽治疗MASH的患者选择、合并症考量及疗效安全性监测提供可实施指导。基于ESSENCE试验72周结果,司美格鲁肽2.4mg每周皮下注射获FDA加速批准用于F2-F3纤维化MASH,组织学终点显著优于安慰剂。
要点
- 司美格鲁肽适用于经NITs确认的F2-F3纤维化MASH患者,不推荐肝活检用于多数患者。
- 常见不良反应为轻度短暂胃肠道事件,需教育患者并滴定剂量以提高耐受性。
- 生活方式干预仍是基石;与resmetirom联用未经研究。
核心结论
- 司美格鲁肽2.4mg每周皮下注射72周可显著改善F2-F3纤维化MASH的组织学终点,获FDA加速批准。
研究设计与样本
- AASLD实践指南更新,基于3期ESSENCE试验的72周 interim 结果及FDA加速批准意见。
主要发现
- MASH缓解且纤维化不恶化:62.9% vs 34.3%安慰剂,p<0.001。
- 纤维化改善≥1期且MASH不恶化:36.8% vs 22.4%安慰剂,p<0.001。
- ESSENCE试验中未因肝酶升高而停药,肝脏安全性良好。
关键数值与推荐
- 候选患者应经VCTE 8-15 kPa、MRE 3.1-4.4 kPa或ELF 9.2-10.5确认F2-F3纤维化。
- VCTE 15-20 kPa、MRE 4.4-5 kPa或ELF 10.5-11.3时,需个体化决策并排除肝硬化。
- 司美格鲁肽未批准用于MASH肝硬化(VCTE>20 kPa、MRE>5.0 kPa、ELF>11.3或门脉高压证据)。
- ALT≥17 U/L或≥20%下降、VCTE LSM≥30%下降、MRE LSM≥20%下降、ELF≥0.5下降提示72周应答改善。
临床怎么用
- 使用NITs而非肝活检选择F2-F3纤维化MASH患者。
- 监测罕见严重风险:急性肾损伤、症状性胆道疾病、胰腺炎、甲状腺C细胞肿瘤、视网膜病变进展及瘦体重丢失。
- 常规肝功能面板仅按临床指征进行。
- 与resmetirom联用未经研究,需个体化。
局限性
- 最终批准尚待长期结局数据。
- 无NITs能可靠预测个体患者组织学应答。
- 应答不佳时获益不确定,需个体化处理及进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy formulation, whose main ingredient is semaglutide, received accelerated FDA approval in August 2025 for treating MASH with moderate-to-advanced fibrosis (consistent with stages F2-F3 fibrosis), based on interim results of the phase 3 ESSENCE trial where 72 weeks of 2.4 mg/week subcutaneous injection resulted in achievement of both primary histologic endpoints: (1) resolution of MASH without worsening of fibrosis (62.9% vs. 34.3% placebo, p <0.001) and (2) ≥1 stage reduction in liver fibrosis without worsening of MASH (36.8% vs. 22.4% placebo, p <0.001); final approval awaits long-term outcomes. Patient Selection: Candidates should have MASH with stage 2-3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8-15 kPa), MRE (3.1-4.4 kPa), or ELF (9.2-10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15-20 kPa), MRE (4.4-5 kPa), or ELF (10.5-11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm 3 . While semaglutide is not approved to treat patients with MASH cirrhosis (VCTE >20 kPa, MRE>5.0 kPa, ELF>11.3, and/or evidence of portal hypertension), those with compensated cirrhosis who are receiving semaglutide for another FDA-approved indication should be monitored carefully. Monitoring and Safety: Semaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. Routine hepatic panels are recommended only as clinically indicated. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient; patient education and dose titration help improve tolerance. Clinicians should monitor for rare but serious risks, including acute kidney injury (from dehydration), symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, and lean mass loss. Treatment Response and Concomitant Therapy: Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use of resmetirom with semaglutide 2.4mg/week has not been studied. While no NITs reliably predict histologic response at the individual patient level, reductions from baseline to 72 weeks of treatment suggest significant improvement in MASH resolution (ALT ≥17 U/L or ≥20%) and fibrosis improvement (VCTE LSM ≥30%; MRE LSM ≥20%; ELF ≥0.5). Non-response may be suspected if ALT or NITs worsen. The benefit is uncertain if a suboptimal response occurs, and may require an individualized approach and further follow-up.
引用
- Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025. PMID: 41201884. doi:10.1097/HEP.0000000000001608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。